| EXEL Market Cap History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the EXEL market cap history going back to 3/5/2010:
Also see: EXEL Shares Outstanding History and EXEL YTD Return |
EXEL Market Cap History — Exelixis Capitalization Over Time
As of 4/27/2026 Exelixis has a market cap of 11.22 billion. Investors often follow the EXEL market cap history to compare the size of the company over time.
This page shows EXEL market capitalization trends over time, with 66 market cap datapoints presented, dating back to 3/5/2010.
| EXEL Market Cap History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EXEL Historical Market Cap: +18.22% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EXEL Stock Price Chart |
| About Exelixis Inc |
| Exelixis, Inc. is an oncology company. Co. is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). We show 66 historical shares outstanding datapoints in our EXEL shares outstanding history coverage, used to compute EXEL market cap on those dates. Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing EXEL market cap history over the course of time is important for investors interested in comparing EXEL's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of EXEL versus a peer is one thing; comparing EXEL market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like EXEL can fluctuate over the course of history. With this page we aim to empower investors researching EXEL by allowing them to research the EXEL market cap history. |
| EXEL Current Stock Quote |
Quotes delayed 20 minutes  Free EXEL Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: The Importance of Market Cap | |
|
Video: The Importance of Market Cap
| EXEL Share Performance |
| Market Cap Peers |
| Exelixis (EXEL) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:
EYE Market Cap History EYEG Market Cap History EYEN Market Cap History EYES Market Cap History EYPT Market Cap History FATE Market Cap History FBIO Market Cap History FBLG Market Cap History FBRX Market Cap History FCRE Market Cap History More Healthcare companies » |
EXEL Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
